Navigation Links
Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio
Date:5/2/2011

JUPITER, Fla. and WAGENINGEN, Netherlands, May 2, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the biopharmaceutical, biofuels and industrial enzyme industries, announced today that its research and development subsidiary, Dyadic Nederland B.V. ("Dyadic Netherlands"), has entered into a research agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and EnGen Bio, Inc.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

Under the agreement, Sanofi Pasteur will fund collaborative research at Dyadic Netherland's research and development facility in Wageningen, The Netherlands, which will utilize Dyadic's proprietary and patented C1 Platform Technology for certain vaccine applications. The research will be conducted under the guidance and direction of Dyadic Netherland's General Manager, Dr. ir. Wim van der Wilden, with coordination by Dr. Mark Alfenito, the President and CEO of EnGen Bio. The research is anticipated to be completed in six to twelve months. All other terms of the research collaboration are confidential.

Sanofi Pasteur, based in Lyon, France, is the largest company entirely dedicated to vaccines. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

EnGen Bio, based in Redwood City, California, is an early stage biopharmaceutical company that is working to develop biopharmaceutical applications for Dyadic's proprietary and patented C1 Platform Technology. For more information, please visit: www.engenbio.com.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "We are very pleased to have the opportunity to work with Sanofi Pasteur and EnGen Bio to further demonstrate the utility of our C1 technology for certain vaccine applications."

About Dyadic

Dyadic is a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the biopharmaceutical, biofuels and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that is dedicated to research and development activities for the benefit of Dyadic, its collaborators and customers. Please visit Dyadic Netherlands' website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New U.S. Patent Issued to Dyadic International
2. Dyadic International to Present at Advanced Biofuels Leadership Conference
3. Dyadic International Introduces Advanced Biofuels Enzyme AlternaFuel® CMAX™ At World Biofuels Markets
4. Dyadic International Reports 2010 Fiscal Year Financial Results
5. Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
6. Dyadic International Reports 2010 Third Quarter Financial Results
7. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
8. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
9. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
10. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
11. Dyadic International Engages The Abraham Group as Strategic Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS Liquid ... the key structural element skin needs to maintain its youthful appearance and Algenist is ... First to market with proprietary collagen water active , Active ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia middle ... 14th through the 16th, the University City Science Center will kick off the ... provides Philadelphia-based middle school educators an opportunity for professional development related to STEM ...
(Date:8/10/2017)... ... August 09, 2017 , ... Okyanos Center for Regenerative Medicine has announced its ... Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime event is free ... from the Ministry of Health’s National Stem Cell Ethics Committee (NSCEC) and regulations laid ...
(Date:8/10/2017)... USA, and CARDIFF, UK (PRWEB) , ... August ... ... and photonics, has announced an agreement establishing Kinokuniya Company Ltd. as its exclusive ... SPIE as the exclusive sales representative for the SPIE Digital Library in Japan. ...
Breaking Biology Technology:
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):